Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap.
However, since the pandemic’s peak, Pfizer has faced headwinds. Declining COVID-19 vaccine sales (down 91% from their $37.8 billion 2022 peak) and falling Paxlovid sales (down 70%), have pressured revenue. Patent expirations for drugs like Eliquis by 2026, along with a 15% stock drop year-to-date, reflect investor concerns over growth. Regulatory hurdles and a $57 billion debt load from acquisitions further complicate its path.
As Pfizer navigates these challenges, it faces rising competition from agile biotech firms wielding AI, gene editing, and mRNA technologies. By 2030, these innovators could surpass Pfizer’s drug discovery dominance, threatening its long-held industry crown.
This post originally appeared at 24/7 Wall St.